Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 16/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 16/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29917885 | 0.89 | GABRA2 (0.51) | GABRA2GABRB2GABRG2GABRB3GABRA5 | |
| SCHEMBL21598054 | 0.89 | GABRA2 (0.51) | GABRA2GABRB2GABRG2GABRB3GABRA5 | |
| SCHEMBL21598049 | 0.87 | GABRA2 (0.52) | GABRA2GABRB2GABRG2GABRB3GABRA5 | |
| SCHEMBL21606681 | 0.85 | NR1H2 (0.49) | GABRA2GABRB2GABRG2GABRB3GABRA5 | |
| SCHEMBL21606542 | 0.80 | RORC (0.62) | GABRA2GABRB2 | |
| SCHEMBL9454901 | 0.77 | GABRA2 (0.57) | GABRA2GABRB2GABRG2GABRB3GABRA5 | |
| SCHEMBL16935771 | 0.77 | GABRA2 (0.54) | GABRA2GABRB2KDM4EPOLB | |
| SCHEMBL21606484 | 0.76 | GABRA2 (0.48) | GABRA2GABRB2GABRG2GABRB3GABRA5 | |
| SCHEMBL21606689 | 0.76 | GABRA2 (0.48) | GABRA2GABRB2GABRG2GABRB3GABRA5 | |
| SCHEMBL22438227 | 0.76 | RXFP1 (0.49) | GABRA2GABRB2GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281823-A1 | PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORgT | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-08 | — | — | US | disclosed |
| EP-3807251-B1 | PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-07 | — | — | EP | disclosed |
| US-11345666-B2 | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-31 | — | — | US | disclosed |
| US-11345666-B2 | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-31 | — | — | US | disclosed |
| EP-3807251-A1 | PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORYT | Janssen Pharmaceutica NV (BE) | 2021-04-21 | — | — | EP | disclosed |
| WO-2019244000-A1 | PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019244000-A1 | PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281823-A1 | PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORgT | RORC, RORB, RORA | GABRA2 1319/4885GABRB2 1183/4885GABRG2 607/4885 |
| US-11345666-B2 | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT | RORC, RORB, RORA | GABRA2 1154/4885GABRB2 984/4885GABRG2 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.